|
Volumn 24, Issue 2, 2016, Pages 93-97
|
Understanding cost and value in hepatitis C therapy
|
Author keywords
Cost effectiveness; Early HCV disease; HCV; HCV therapy; Hepatitis C; HIV; Insurance; Payers
|
Indexed keywords
ARTICLE;
COST EFFECTIVENESS ANALYSIS;
DRUG INDUSTRY;
EDUCATION PROGRAM;
FOLLOW UP;
HEALTH CARE COST;
HEPATITIS C;
HUMAN;
LIVER CIRRHOSIS;
MEDICARE;
OUTCOME ASSESSMENT;
PHARMACY BENEFIT MANAGER;
QUALITY ADJUSTED LIFE YEAR;
QUALITY OF LIFE;
SENSITIVITY ANALYSIS;
COST BENEFIT ANALYSIS;
ECONOMICS;
HEALTH CARE DELIVERY;
HEPATITIS C, CHRONIC;
TREATMENT OUTCOME;
ANTIVIRUS AGENT;
ANTIVIRAL AGENTS;
COST-BENEFIT ANALYSIS;
HEALTH SERVICES ACCESSIBILITY;
HEPATITIS C, CHRONIC;
HUMANS;
TREATMENT OUTCOME;
|
EID: 84990060411
PISSN: 21615861
EISSN: 21615853
Source Type: Journal
DOI: None Document Type: Article |
Times cited : (5)
|
References (8)
|